Prophylactic Endoscopic Sclerotherapy of Esophageal Varices in Liver Cirrhosis - Long-Term Follow-Up and Final Results of a Multicenter Prospective Controlled Randomized Trial in Vienna

R. Pötzi; P. Bauer; R. Schöfl; W. Reichel; E. Kerstan; F. Renner; A. Gangl

doi:10.1055/s-2007-1010316

Endoscopy, Table of Contents

Endoscopy 1993; 25(4): 287-289
DOI: 10.1055/s-2007-1010316

Short Communications

Prophylactic Endoscopic Sclerotherapy of Esophageal Varices in Liver Cirrhosis - Long-Term Follow-Up and Final Results of a Multicenter Prospective Controlled Randomized Trial in Vienna

R. Pötzi¹ , P. Bauer² , R. Schöfl¹ , W. Reichel³ , E. Kerstan³ , F. Renner¹ , A. Gangl¹

¹Clinic of Internal Medicine IV, Department of Gastroenterology and Hepatology, University of Vienna, Austria
²Institute of Medical Documentation and Statistics, University of Cologne, Germany
³Department of Medicine IV, Wilhelminenspital, Vienna, Austria

Abstract

PDF Download

Abstract

This study reports the final results of a randomized multicenter trial on prophylactic endoscopic sclerotherapy of large esophageal varices in patients with liver cirrhosis. Forty-one patients received prophylactic treatment and 41 patients were in the control group. A first analysis 3 years after beginning the study revealed no significant difference in the distribution of the bleeding free intervals between both groups, but indicated a tendency towards longer survival of patients with prophylactic sclerotherapy. The follow-up of patients was continued for an additional 3 years. After this time, 53.7 % of patients in the sclerotherapy group and 39.1 % of patients in the control group were still alive. During the study period of 6 years, variceal bleeding was observed in 31.7 % of patients in the sclerotherapy group and in 36.6 % of patients in the control group. Neither survival nor incidence of bleeding were statistically different between the two groups. The etiology of cirrhosis did not influence the survival.

PDF (463 kb)